Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 8/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10756385 | 0.85 | TSHR (0.48) | TSHRSMN1; SMN2TDP1HSD17B10ALDH1A1 | |
| SCHEMBL11741640 | 0.83 | TSHR (0.50) | TSHRSMN1; SMN2TDP1HSD17B10ALDH1A1 | |
| SCHEMBL15776706 | 0.82 | TDP1 (0.46) | TSHRSMN1; SMN2TDP1HSD17B10ALDH1A1 | |
| SCHEMBL31468771 | 0.82 | TDP1 (0.46) | TSHRSMN1; SMN2TDP1HSD17B10ALDH1A1 | |
| SCHEMBL7469818 | 0.82 | TSHR (0.47) | TSHRSMN1; SMN2TDP1HSD17B10ALDH1A1 | |
| SCHEMBL5200620 | 0.81 | TSHR (0.48) | TSHRSMN1; SMN2TDP1HSD17B10ALDH1A1 | |
| SCHEMBL6645181 | 0.81 | TSHR (0.48) | TSHRSMN1; SMN2TDP1HSD17B10ALDH1A1 | |
| SCHEMBL27475187 | 0.79 | TSHR (0.46) | TSHRSMN1; SMN2TDP1HSD17B10ALDH1A1 | |
| SCHEMBL3961070 | 0.78 | TSHR (0.58) | TSHRSMN1; SMN2TDP1HSD17B10ALDH1A1 | |
| SCHEMBL6962624 | 0.77 | TSHR (0.41) | TSHRSMN1; SMN2TDP1HSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240417377-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING ß-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEA | SYMBERIX, INC. | 2024-12-19 | — | — | US | disclosed |
| US-12017994-B2 | Compounds, compositions, and methods for selectively inhibiting β-glucuronidases and alleviating side effects associated with drug treatment induced diarrhea | SYMBERIX, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12017994-B2 | Compounds, compositions, and methods for selectively inhibiting β-glucuronidases and alleviating side effects associated with drug treatment induced diarrhea | SYMBERIX, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12017994-B2 | Compounds, compositions, and methods for selectively inhibiting β-glucuronidases and alleviating side effects associated with drug treatment induced diarrhea | SYMBERIX, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| CN-112955433-A | Compounds, compositions and methods for selectively inhibiting beta-glucuronidase and reducing side effects associated with drug therapy-induced diarrhea | 赛伯克斯股份有限公司 | 2021-06-11 | — | — | CN | disclosed |
| US-20210094917-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING B-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEA | SYMBERIX, INC. | 2021-04-01 | — | — | US | disclosed |
| US-20210094917-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING B-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEA | SYMBERIX, INC. | 2021-04-01 | — | — | US | disclosed |
| EP-3710003-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING Beta- -GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEA | Symberix, Inc. (US) | 2020-09-23 | — | — | EP | disclosed |
| WO-2019051185-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING β-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEA | SYMBERIX, INC. (US) | 2019-03-14 | — | — | WO | disclosed |
| WO-2019051185-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING β-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEA | SYMBERIX, INC. (US) | 2019-03-14 | — | — | WO | disclosed |
| WO-1996013485-A1 | PYRIDOPYRIMIDONES, QUINOLINES AND FUSED N-HERETOCYCLES AS BRADYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-05-09 | — | — | WO | disclosed |
| US-4782055-A | Imidazopyridine compounds useful in the treatment of ulcers | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-11-01 | — | — | US | disclosed |
| EP-0228006-A1 | Imidazopyridine compounds and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1987-07-08 | — | — | EP | disclosed |
| US-4536591-A | Insecticidal [1,1'-biphenyl]-3-ylmethyl esters | FMC CORPORATION (US) | 1985-08-20 | — | — | US | disclosed |
| EP-0143153-A2 | Insecticidal 1,1'-Biphenyl -3-ylmethyl esters, their production and use and compositions containing them | FMC Corporation (US) | 1985-06-05 | — | — | EP | disclosed |
| EP-0143152-A2 | Insecticidal (1,1'-biphenyl)-3-ylmethyl esters, their production and use and compositions containing them | FMC Corporation (US) | 1985-06-05 | — | — | EP | disclosed |
| US-4402973-A | Insecticidal (1,1'-biphenyl)-3-ylmethyl esters | FMC CORPORATION (US) | 1983-09-06 | — | — | US | disclosed |
| US-4375476-A | MITICIDES | FMC CORPORATION (US) | 1983-03-01 | — | — | US | disclosed |
| US-4329518-A | INSECTICIDES, ACARICIDES, MITICIDES | FMC CORPORATION (US) | 1982-05-11 | — | — | US | disclosed |
| EP-0049977-A1 | Insecticidal (1,1'-biphenyl)-3-ylmethyl esters, their production and use and compositions containing them | FMC Corporation (US) | 1982-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240417377-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING ß-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEA | GUSB, SI, ENGASE | TSHR 4493/4885SMN1; SMN2 4150/4885TDP1 2481/4885 |
| US-12017994-B2 | Compounds, compositions, and methods for selectively inhibiting β-glucuronidases and alleviating side effects associated with drug treatment induced diarrhea | GUSB, SI, ENGASE | TSHR 4477/4885SMN1; SMN2 4192/4885TDP1 2534/4885 |
| US-20210094917-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING B-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEA | GUSB, SI, UGT2B7 | TSHR 4350/4885SMN1; SMN2 4295/4885TDP1 2574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.